Congress Materials

Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Sands BE, Rubin DT, Panés J, Gecse KB, Leung Y, Goetsch M, Wang W, Shan K, Woolcott J, Smith CC, Wosik K, Schreiber S May 9, 2023 DDW May 2023 Ulcerative Colitis

Achievement of Corticosteroid-Free Clinical Endpoints in Subjects With Ulcerative Colitis: An Analysis of the Phase 3 Elevate UC 52 Trial

View Presentation
Poster
Magro F, Peyrin-Biroulet L, Sands BE, Danese S, Jairath V, Goetsch M, Bhattacharjee A, Wu J, Branquinho D, Modesto I, Feagan BG May 9, 2023 DDW May 2023 Ulcerative Colitis

Achievement of Stringent Histologic and Composite Endpoints in Subjects With Moderately to Severely Active Ulcerative Colitis Treated With Etrasimod: A Post Hoc Analysis of the Phase 3 Elevate UC 52 and Elevate UC 12 Trials

View Presentation
Poster
Long MD, Afzali A, Fischer M, English E, Zhang X, Hudesman D, Abdalla M, McCabe R, Cohen B, Ungaro R, Harlan W, Hanson J, Konijeti G, Polyak S, Ritter T, Salzberg B, Seminerio J, Sharma P, Herfarth H May 9, 2023 DDW May 2023 Ulcerative Colitis

Association of Early Clinical Efficacy Factors With 1-Year Response and Remission to Tofacitinib in Moderate to Severe Ulcerative Colitis in a Real World Prospective Multicenter Study (Tour)

View Presentation
Poster
Vermeire S, * Yarur AJ, * Rubin DT, Dubinsky MC, Regueiro M, Irving PM, Peyrin-Biroulet L, Goetsch M, Gu G, Wu J, Modesto I, McDonnell A, Rabbat CJ, Green J, Anthopoulos P May 9, 2023 DDW May 2023 Ulcerative Colitis

Characterization of Cardiac Conduction Abnormalities Reported in the Phase 3 Elevate Programme

View Presentation
Poster
Siegmund B, Ryan R, Abreu MT, Vermeire S, Dotan I, Goetsch M, Crosby C, Woolcott J, Komori HK, Danese S May 9, 2023 DDW May 2023 Ulcerative Colitis

Characterization of Plasma Inflammatory Protein Abundance in Patients With Ulcerative Colitis Treated With Etrasimod: An Exploratory Analysis of the Phase 3 Elevate UC 52 and Elevate UC 12 Trials

View Presentation
Poster
Siegmund B, Komori HK, Abreu MT, Vermeire S, Dotan I, Goetsch M, Crosby C, Ryan R, Woolcott J, Danese S May 9, 2023 DDW May 2023 Ulcerative Colitis

Effect of Etrasimod on Immune Cell Subsets in Colonic Tissue of Patients With Ulcerative Colitis: Immunophenotyping Analysis of Colon Biopsy Samples From the Phase 3 Elevate UC 52 and Elevate UC 12 Trials

View Presentation
Poster
Peyrin-Biroulet L, * Dubinsky MC, * Sands BE, Panés J, Schreiber S, Reinisch W, Feagan BG, Danese S, Yarur AJ, D’Haens G, Goetsch M, Wosik K, Wu J, Modesto I, McDonnell A, Bartolome L, Rabbat CJ, Vermeire S May 9, 2023 DDW May 2023 Ulcerative Colitis

Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Isolated Proctitis: A Subgroup Analysis of the Phase 3 Elevate UC 52 and Elevate UC 12 Trials

View Presentation
Poster
Vermeire S, * Sands BE, * Dubinsky MC, Feagan BG, Panaccione R, Jairath V, Yarur AJ, Chiorean MV, Panés J, Goetsch M, Rabbat CJ, Shah P, Wu J, Ghosh S May 9, 2023 DDW May 2023 Ulcerative Colitis

Efficacy of Etrasimod at Week 52 Among Subjects Who Reached Clinical Response at Week 12: Post Hoc Analysis of the Phase 3 Elevate UC 52 Trial

View Presentation
Poster
Chaparro M, Armuzzi A, Irving PM, Allez M, Dubinsky MC, Sands BE, Goetsch M, Wang W, Shan K, Woolcott J, Bartolome L, Wosik K, Panaccione R May 9, 2023 DDW May 2023 Ulcerative Colitis

Efficacy of Etrasimod on Symptomatic Relief in Patients With Ulcerative Colitis: An Analysis of the Phase 3 Elevate UC 52 and Elevate UC 12 Trials

View Presentation
Poster
Regueiro M, Siegmund B, Yarur AJ, Steinwurz F, Gecse KB, Goetsch M, Bhattacharjee A, Wu J, Green J, McDonnell A, Crosby C, Lazin K, Branquinho D, Modesto I, Abreu MT May 9, 2023 DDW May 2023 Ulcerative Colitis

Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Rates From the Phase 3 Elevate UC 52 and Elevate UC 12 Clinical Trials

View Presentation